These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33879070)

  • 1. Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy.
    Zhang J; Yang L; Ding Y
    BMC Cardiovasc Disord; 2021 Apr; 21(1):194. PubMed ID: 33879070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
    Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased rho-kinase activity in hypertensive patients with left ventricular hypertrophy.
    Gabrielli L; Winter JL; Godoy I; McNab P; Padilla I; Cordova S; Rigotti P; Novoa U; Mora I; García L; Ocaranza MP; Jalil JE
    Am J Hypertens; 2014 Jun; 27(6):838-45. PubMed ID: 24363278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD206 and CD163 on intermediate CD14
    Li X; Du N; Xu G; Zhang P; Dang R; Jiang Y; Zhang K
    Virus Res; 2018 Jul; 253():92-102. PubMed ID: 29857122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased circulating endothelial progenitor cell levels and function in essential hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Lee CW; Huang PH; Huang SS; Leu HB; Huang CC; Wu TC; Chen JW; Lin SJ
    Hypertens Res; 2011 Sep; 34(9):999-1003. PubMed ID: 21654753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Müller-Brunotte R; Kahan T; López B; Edner M; González A; Díez J; Malmqvist K
    J Hypertens; 2007 Sep; 25(9):1958-66. PubMed ID: 17762662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monocyte inflammatory profile is specific for individuals and associated with altered blood lipid levels.
    Patel VK; Williams H; Li SCH; Fletcher JP; Medbury HJ
    Atherosclerosis; 2017 Aug; 263():15-23. PubMed ID: 28570862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD163 levels, pro- and anti-inflammatory cytokine secretion of monocytes in children with pulmonary tuberculosis.
    Aktas Cetin E; Pur Ozyigit L; Gelmez YM; Cakir E; Gedik AH; Deniz G
    Pediatr Pulmonol; 2017 May; 52(5):675-683. PubMed ID: 27685837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of and risk factors for abnormal left ventricular geometrical patterns in hypertensive subjects administered irbesartan.
    Huang C; Huang Y; Zhong Q; Cai A; Feng YQ
    J Clin Lab Anal; 2021 Mar; 35(3):e23688. PubMed ID: 33389756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asiatic acid alleviates cardiovascular remodelling in rats with L-NAME-induced hypertension.
    Bunbupha S; Prachaney P; Kukongviriyapan U; Kukongviriyapan V; Welbat JU; Pakdeechote P
    Clin Exp Pharmacol Physiol; 2015 Nov; 42(11):1189-97. PubMed ID: 26234646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of irbesartan on left ventricular mass and arterial stiffness in hypertensive patients.
    Park CG; Ahn JC; Hong SJ; Kim EJ; Lee SJ; Park SM; Seo HS; Oh DJ
    Korean J Intern Med; 2006 Jun; 21(2):103-8. PubMed ID: 16913439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients.
    González A; López B; Martín-Raymondi D; Lozano E; Varo N; Barba J; Serrano M; Díez J
    J Hypertens; 2005 Dec; 23(12):2297-304. PubMed ID: 16269972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between growth differentiation factor 15 and left ventricular hypertrophy in hypertensive patients and healthy adults.
    Kou H; Jin X; Gao D; Ma R; Dong X; Wei J; Wang X
    Clin Exp Hypertens; 2018; 40(1):8-15. PubMed ID: 29035099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left ventricular hypertrophy is associated with increased sirtuin level in newly diagnosed hypertensive patients.
    Duman H; Bahçeci I; Çinier G; Duman H; Bakırcı EM; Çetin M
    Clin Exp Hypertens; 2019; 41(6):511-515. PubMed ID: 30230925
    [No Abstract]   [Full Text] [Related]  

  • 18. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
    Pouleur AC; Uno H; Prescott MF; Desai A; Appelbaum E; Lukashevich V; Smith BA; Dahlöf B; Solomon SD;
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):483-90. PubMed ID: 21746765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial.
    Kurland L; Hallberg P; Melhus H; Liljedahl U; Hashemi N; Syvänen AC; Lind L; Kahan T
    Am J Hypertens; 2008 Jul; 21(7):836-9. PubMed ID: 18464745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.